Vista Investment Partners II LLC Invests $511,000 in McKesson Co. (NYSE:MCK)

Vista Investment Partners II LLC acquired a new position in shares of McKesson Co. (NYSE:MCK - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 896 shares of the company's stock, valued at approximately $511,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MCK. FMR LLC grew its position in McKesson by 17.3% during the 3rd quarter. FMR LLC now owns 2,968,239 shares of the company's stock worth $1,467,557,000 after purchasing an additional 438,423 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in McKesson by 55.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,189,377 shares of the company's stock worth $588,048,000 after purchasing an additional 425,875 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of McKesson by 126.8% during the 3rd quarter. Janus Henderson Group PLC now owns 574,440 shares of the company's stock valued at $283,903,000 after acquiring an additional 321,119 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of McKesson during the 4th quarter valued at $178,397,000. Finally, Raymond James Financial Inc. purchased a new position in shares of McKesson during the 4th quarter valued at $128,125,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Trading Down 1.9 %

NYSE MCK traded down $12.26 on Wednesday, reaching $640.93. The company's stock had a trading volume of 694,919 shares, compared to its average volume of 819,051. The firm has a market cap of $80.32 billion, a PE ratio of 29.35, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. The business has a 50-day moving average price of $605.54 and a 200 day moving average price of $569.47. McKesson Co. has a 52 week low of $464.42 and a 52 week high of $663.61.

Remove Ads

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Analysts anticipate that McKesson Co. will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be issued a $0.71 dividend. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $2.84 annualized dividend and a yield of 0.44%. McKesson's dividend payout ratio (DPR) is presently 13.00%.

Insiders Place Their Bets

In other McKesson news, EVP Leann B. Smith sold 188 shares of the stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total value of $114,602.92. Following the sale, the executive vice president now directly owns 1,051 shares in the company, valued at approximately $640,679.09. This trade represents a 15.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Brian S. Tyler sold 8,961 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $597.99, for a total transaction of $5,358,588.39. Following the completion of the sale, the chief executive officer now owns 60,664 shares in the company, valued at approximately $36,276,465.36. This trade represents a 12.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,689 shares of company stock worth $11,187,351. Company insiders own 0.11% of the company's stock.

Analyst Ratings Changes

MCK has been the subject of a number of research analyst reports. Citigroup cut their target price on shares of McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a research report on Friday, January 10th. Morgan Stanley boosted their target price on shares of McKesson from $612.00 to $642.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 17th. StockNews.com lowered shares of McKesson from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th. Mizuho initiated coverage on shares of McKesson in a research report on Wednesday, December 4th. They set a "neutral" rating and a $630.00 target price for the company. Finally, Wells Fargo & Company boosted their target price on shares of McKesson from $535.00 to $641.00 and gave the stock an "equal weight" rating in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, McKesson has an average rating of "Moderate Buy" and a consensus price target of $645.79.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.